Company information

Company listing information, company shareholders as well as key dates and contact details.

This share factsheet isn’t an investment recommendation. We don’t offer personal advice so if you’re unsure, please seek independent advice. Remember, the value of investments can fall as well as rise and you may get back less than you invest.

Business summary

BVX has identified a unique, cancer-restricted antigen fingerprint, absent from healthy cells, which can be exploited to produce cancer selective therapeutics. The Bi-Cygni® technology has been developed to exploit this concept and expedite the development of bispecific therapeutics with an improved therapeutic index. Based on BVX's work to date, these ADCs demonstrate superior potency and tumour selectivity compared to conventional ADCs. The main country of operation is in the UK.



Listing information

  • Share information

  • Sector: Pharmaceuticals & Biotechnology
  • ISIN: GB00BNXH3K91
  • Market Sector: AIM
  • Market Segment: ASQ1
  • Main Indices: FTSE AIM All-Share
  • Country of register: Great Britain
  • Currency: British Pound
  • Market Cap: £10.73m
  • NMS: 7,500
  • Shares in issue: 82.53m
  • Date Listed: n/a
  • Registrar: n/a
  • Exchange: London stock exchange
  • Additional listings

  • Domestic listings: n/a
  • Overseas listings: n/a

Key dates

  • Dividends

  • Ex-div date (interim): n/a
  • Latest Pay Date (interim): n/a
  • View dividends
  • Meetings

  • AGM: 24/07/2024
  • EGM: n/a

Company shareholders

Last updated 31/12/2023

*Major shareholders are individuals or institutions that own more than 3% of the company’s shares and have been reported in the annual accounts.

View company shareholders breakdown

Contact details

Address: Mereside, Alderley Park ,Alderley Edge, Macclesfield, United Kingdom, SK10 4TG

Website: n/a


Thinking about investing?

In order to invest, you’ll first need to be a Smart Investor customer. Compare our accounts and choose the right one for you.

Compare accounts

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

Copyright © 2024 Refinitiv, an LSEG business. All rights reserved.